Scholl S - Search Results

1

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.

Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C; Study Alliance Leukemia (SAL). Hanoun M, et al. Among authors: scholl s. J Cancer Res Clin Oncol. 2023 Jul;149(8):4611-4621. doi: 10.1007/s00432-022-04356-9. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36167894 Free PMC article. Clinical Trial.

2

Clinical implications of molecular genetic aberrations in acute myeloid leukemia.

Scholl S, Fricke HJ, Sayer HG, Höffken K. Scholl S, et al. J Cancer Res Clin Oncol. 2009 Apr;135(4):491-505. doi: 10.1007/s00432-008-0524-x. Epub 2009 Jan 6. J Cancer Res Clin Oncol. 2009. PMID: 19125300 Review.

3

Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkin's lymphoma.

Ritter E, Husain RA, Hinderhofer K, Prell T, Fricke HJ, Scholl S, Hochhaus A, La Rosée P. Ritter E, et al. Among authors: scholl s. Ann Hematol. 2011 Jul;90(7):857-9. doi: 10.1007/s00277-010-1106-y. Ann Hematol. 2011. PMID: 21061009 No abstract available.

4

Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation.

Rommeley M, Spies-Weisshart B, Schilling K, Hochhaus A, Sayer HG, Scholl S. Rommeley M, et al. Among authors: scholl s. J Cancer Res Clin Oncol. 2011 Sep;137(9):1293-300. doi: 10.1007/s00432-011-0989-x. Epub 2011 Jun 29. J Cancer Res Clin Oncol. 2011. PMID: 21713449

5

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer FD, Hochhaus A, Fischer T, Scholl S. Zirm E, et al. Among authors: scholl s. Br J Haematol. 2012 May;157(4):483-92. doi: 10.1111/j.1365-2141.2012.09085.x. Epub 2012 Mar 13. Br J Haematol. 2012. PMID: 22409268 Free article.

6

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A. Metzelder SK, et al. Among authors: scholl s. Leukemia. 2012 Nov;26(11):2353-9. doi: 10.1038/leu.2012.105. Epub 2012 Apr 16. Leukemia. 2012. PMID: 22504140

7

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.

Schnetzke U, Fischer M, Kuhn AK, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S. Schnetzke U, et al. Among authors: scholl s. J Cancer Res Clin Oncol. 2013 Apr;139(4):605-15. doi: 10.1007/s00432-012-1362-4. Epub 2012 Dec 21. J Cancer Res Clin Oncol. 2013. PMID: 23263202

8

Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia.

Yomade O, Spies-Weisshart B, Glaser A, Schnetzke U, Hochhaus A, Scholl S. Yomade O, et al. Among authors: scholl s. Ann Hematol. 2013 Aug;92(8):1071-7. doi: 10.1007/s00277-013-1734-0. Epub 2013 Apr 5. Ann Hematol. 2013. PMID: 23558906

9

Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD).

Spies-Weisshart B, Schilling K, Böhmer F, Hochhaus A, Sayer HG, Scholl S. Spies-Weisshart B, et al. Among authors: scholl s. J Cancer Res Clin Oncol. 2013 Aug;139(8):1397-404. doi: 10.1007/s00432-013-1451-z. Epub 2013 Jun 1. J Cancer Res Clin Oncol. 2013. PMID: 23728535

10

The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.

Schnetzke U, Fischer M, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S. Schnetzke U, et al. Among authors: scholl s. Leuk Res. 2013 Nov;37(11):1557-64. doi: 10.1016/j.leukres.2013.08.004. Epub 2013 Aug 12. Leuk Res. 2013. PMID: 23998902

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters